ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ THUỐC ỨC CHẾ CDK4/6 KẾT HỢP NỘI TIẾT TRONG ĐIỀU TRỊ BƯỚC MỘT UNG THƯ VÚ TÁI PHÁT, DI CĂN, THỤ THỂ NỘI TIẾT DƯƠNG TÍNH, HER2 ÂM TÍNH

Abstract

Background: We aimed to assess the response rate to the regimen of CDK4/6 inhibitors combined with endocrine therapy and first-line treatment and commented on some side effects of CDK4/6 inhibitors combined with endocrine therapy. Methods: Retrospective study on patients with metastatic recurrent breast cancer, hormone receptor positive, HER2 negative, without previous endocrine therapy for metastasis at Vietnam National Cancer Hospital. We evaluated clinical characteristics, response rate and toxicities. Results: A total of 27 patients were included, 63% of patients were postmenopausal. The majority of cases (92.6%) ECOG 0. Age <65 accounts for 64,7%. Histopathology: 96,3% are invasive ductal carcinoma, 81,5% histological grade 2. There are 7,4% of luminal HER2+ types transformed into HER2- after re-biopsy of metastatic recurrence lesions. There was 74,1% partial response, 3,7% complete response, and 18,5% stable disease. Clinical benefit: 96.3%. The main toxicities are neutropenia (92,5%), grade 2 hypoerythrocytosis in 25.9%, and increased liver enzymes in 7.4%. Conclusion: CDK4/6 inhibitors in the first-line treatment of hormone receptor-positive, Her2-negative metastatic recurrent breast cancer provide high response rates and clinical benefits, with mainly granulocytopenic toxicity. We need more real-world clinical data on treatment.